Hemab Therapeutics Inc.
(NASDAQ:COAG) on Sunday presented new clinical data for its lead candidate HMB-002 in Von Willebrand disease (VWD) and introduced HMB-003, a new program targeting heavy menstrual bleeding, at the International Society on Thrombosis and Hemostasis (ISTH) 2026 Congress.
The company said the latest findings support its strategy of addressing the underlying biology of bleeding disorders rather than relying on traditional replacement therapies. • Hemab Therapeutics stock is at critical resistance.
What's behind COAG new highs?
HMB-002 Shows Early Signs Of Potential In VWD According to Benny Sørensen, CEO of Hemab, the latest HMB-002 data demonstrated proof of mechanism in VWD and included preliminary clinical observations on bleeding events.
